Infliximab: adverse events as reason for treatment discontinuation

被引：0
作者：
Moustou, A. -E. [1 ]
Papoutsaki, M. [1 ]
Vergou, T. [1 ]
Masouri, S. [1 ]
Sachlas, A. [2 ]
Antoniou, C. [1 ]
机构：
[1] A Sygros Hosp, Dept Dermatol 1, Athens, Greece
[2] Univ Peloponnese, Dept Nursing, Sparta, Greece
来源：
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2016年 / 30卷
关键词：
adverse events; infliximab; treatment discontinuation;
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P184
引用
收藏
页码：93 / 93
页数：1
相关论文
共 50 条
  • [21] Higher Infliximab Levels Are Not Associated With an Increase in Adverse Events in Inflammatory Bowel Disease
    Greener, Tomer
    Kabakchiev, Boyko
    Steinhart, A. Hillary
    Silverberg, Mark S.
    INFLAMMATORY BOWEL DISEASES, 2018, 24 (08) : 1808 - 1814
  • [22] Impact of discontinuation of cephazolin prophylaxis on the incidence of postoperative adverse events in cataract surgery
    Uchida, Kazutaka
    Takahama, Keita
    Higashi, Kenshiro
    Kusano, Yuki
    Matsumoto, Koki
    Nakagawa, Yoshihiro
    Oda, Kazutaka
    JOURNAL OF PHARMACEUTICAL HEALTH CARE AND SCIENCES, 2025, 11 (01):
  • [23] Recurrence of Uveitis after Discontinuation of Infliximab
    Shakoor, Akbar
    Esterberg, Elizabeth
    Acharya, Nisha R.
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2014, 22 (02) : 96 - 101
  • [24] Infliximab in ulcerative colitis: real-life analysis of factors predicting treatment discontinuation due to lack of response or colectomy: ECIA (ACAD Colitis and Infliximab Study)
    Fernandez-Salazar, Luis
    Munoz, Fernando
    Barrio, Jesus
    Munoz, Concepcion
    Pajares, Ramon
    Rivero, Montserrat
    Prieto, Vanessa
    Legido, Jesus
    Bouhmidi, Abdel
    Herranz, Maite
    Fernandez, Nereida
    Sanchez-Ocana, Ramon
    Joao, Diana
    Santos, Fernando
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2016, 51 (02) : 186 - 195
  • [25] Reason's accident causation model: Application to adverse events in acute care
    Elliott, Malcolm
    Page, Karen
    Worrall-Carter, Linda
    CONTEMPORARY NURSE, 2012, 43 (01) : 22 - 28
  • [26] Clinical Significance of Autoantibodies Induced by Infliximab Treatment: Two-Year Follow-up after Infliximab Discontinuation
    Novak, Srdan
    Anic, Branimir
    Anic, Felina
    Cerovac, Mislav
    Cikes, Nada
    ACTA DERMATOVENEROLOGICA CROATICA, 2011, 19 (03) : 156 - 160
  • [27] Usefulness of Nutritional Assessment Indicators in Predicting Treatment Discontinuation Due to Adverse Events from PARP Inhibitors in Ovarian Cancer Patients
    Tanaka, Yoshiaki
    Inoue, Daisuke
    Tsuyoshi, Hideaki
    Nakamura, Yuriko
    Kato, Masato
    Kato, Masataka
    Niwa, Kentaro
    Yashiro, Kenji
    Orisaka, Makoto
    Yoshida, Yoshio
    CANCERS, 2024, 16 (21)
  • [28] Long-term vaginal ring pessary use: discontinuation rates and adverse events
    Sarma, S.
    Ying, T.
    Moore, K. H.
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2009, 116 (13) : 1715 - 1721
  • [29] Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients
    Hoffmann, C.
    Welz, T.
    Sabranski, M.
    Kolb, M.
    Wolf, E.
    Stellbrink, H-J
    Wyen, C.
    HIV MEDICINE, 2017, 18 (01) : 56 - 63
  • [30] Treatment Patterns Following Discontinuation of Adalimumab, Etanercept, and Infliximab in a US Managed Care Sample
    Jason Yeaw
    Crystal Watson
    Kathleen M. Fox
    Vernon F. Schabert
    Seth Goodman
    Shravanthi R. Gandra
    Advances in Therapy, 2014, 31 : 410 - 425
12345